Medicine
Litfulo 50 mg capsule
Litfulo 50 mg capsule is a prescription medicine containing Ritlecitinib for oral use, marketed by Pfizer Laboratories, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Ambient
Store LITFULO at 20°C to 25°C (68°F to 77°F), excursions permitted between…
Key facts
- Active ingredient (INN)
- Ritlecitinib
- Brand
- Litfulo
- Strength
- 50 mg
- Dosage form
- Capsule
- Route
- Oral
- Packs
- 28 capsules
- Marketing authorisation holder
- Pfizer Laboratories
- Manufacturer
- Pfizer Laboratories2 labelers on the register
- Origin register
- US FDA, United States
- Storage
- Store LITFULO at 20°C to 25°C (68°F to 77°F), excursions permitted between 15°C to 30°C (59°F to 86°F).
- Cold chain
- Not required on record
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- L04AF08 Ritlecitinib
- HS code (indicative)
- 3004.90Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 6 July 2023
- Identifiers
- RxCUI 2641601, 2641607DailyMed set ID 6b2f9446-fb23-4741-b73a-5a2f993733c3, 1882f799-61b0-4813-965a-4910c4ae419cNDC 0069-0334, 63539-334Application NDA215830
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 28 capsule in 1 bottle | 0069-0334-28 | Pfizer Laboratories | 6 July 2023 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Clinical summary
Ritlecitinib is a kinase inhibitor indicated for the treatment of severe alopecia areata in adults and adolescents 12 years and older. It is available as capsules for oral use. MedsAcross supplies Ritlecitinib for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about RitlecitinibFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- Litfulo prescribing information (US Pharmaceuticals) · U.S. National Library of Medicine, DailyMed
- Litfulo: European public assessment report (EPAR) · European Medicines Agency
Need Litfulo 50 mg capsule for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.